The effective registration allows selling stockholders to immediately sell shares into the market, creating a persistent overhang. With warrants exercisable at $2.27-$2.575 (deeply in-the-money vs $4.07), holders have strong incentive to exercise and sell. Monitor for volume spikes and accelerated selling. The cross-filing S-1 context confirms this is a resale shelf, not a primary offering — the company gets no cash from these trades.
Price Chart
Executive Summary
The SEC declared Lantern Pharma's S-1 registration statement effective on June 18, 2026, enabling selling stockholders to resell up to 2,242,719 shares of common stock issuable upon exercise of warrants. The company receives no proceeds from these sales, only potential cash from warrant exercises. This creates a near-term overhang of up to ~2.24M shares (significant relative to the $48M market cap) that can be sold into the market at any time.
Key Facts
- Effectiveness date: June 18, 2026
- Up to 2,242,719 shares of common stock registered for resale by selling stockholders
- Shares are issuable upon exercise of warrants: 2,135,923 warrants at $2.27/share and 106,796 warrants at $2.575/share
- Company will not receive any proceeds from sales by selling stockholders
- Warrants were issued in a private placement on May 14, 2026
- Last reported stock price on June 11, 2026 was $4.07 per share
Financial Impact
Up to 2.24M shares of potential dilution overhang, representing ~46% of current shares outstanding (implied from $48M market cap at $4.07/share = ~11.8M shares outstanding). No proceeds to company from resales.
Risk Factors
- Near-term selling pressure from warrant holders exercising and flipping shares
- Dilution overhang of ~2.24M shares could cap upside and increase volatility
- No new capital raised for the company from these resales
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-002072 |
| Document: 9999999995-26-002072-index.html | 9999999995-26-002072 |
| Document: 9999999995-26-002072.txt | 9999999995-26-002072 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEF 14A | $0.6564 | awaiting T+60 | — | $0.6240 (+4.94%) |
Oct 13, 2026 13d ago | SC 13G/A | $0.7107 | awaiting T+60 | — | $0.6240 (−12.20%) |
Oct 1, 2026 25d ago | 8-K | $0.8601 | awaiting T+60 | — | $0.6240 (+27.45%) |
Sep 30, 2026 26d ago | 8-K | $1.00 | awaiting T+60 | — | $0.6240 (+37.60%) |
Sep 30, 2026 26d ago | 424B5 | $1.01 | awaiting T+60 | — | $0.6240 (+38.22%) |
Sep 23, 2026 4w ago | 8-K | $1.21 | awaiting T+60 | — | $0.6240 (−48.43%) |
Sep 23, 2026 4w ago | 8-K | $1.39 | awaiting T+60 | — | $0.6240 (−55.11%) |
Aug 14, 2026 10w ago | 8-K | $2.65 | awaiting T+60 | — | $0.6240 (−76.45%) |
Jun 22, 2026 18w ago | EFFECT | $3.88 $1.70 | ▲ +56.19% | ▲ +57.93% | $0.6240 (+83.92%) |
May 15, 2026 23w ago | 8-K | $3.00 $2.66 | ▼ −11.33% | ▼ −16.18% | $0.6240 (−79.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers